Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial-Reference-Cited by-同舟云学术

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Published:2016-01-14 Issue:2 Volume:127 Page:208-215
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fischer Kirsten¹,Bahlo Jasmin¹,Fink Anna Maria¹,Goede Valentin¹,Herling Carmen Diana¹,Cramer Paula¹,Langerbeins Petra¹,von Tresckow Julia¹,Engelke Anja¹,Maurer Christian¹,Kovacs Gabor¹,Herling Marco¹,Tausch Eugen²,Kreuzer Karl-Anton¹,Eichhorst Barbara¹,Böttcher Sebastian³,Seymour John F.⁴,Ghia Paolo⁵,Marlton Paula⁶⁷,Kneba Michael³,Wendtner Clemens-Martin¹⁸,Döhner Hartmut²,Stilgenbauer Stephan²,Hallek Michael¹⁹

Affiliation:

1. Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany;

2. Department of Internal Medicine III, University of Ulm, Ulm, Germany;

3. Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany;

4. Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia;

5. Division of Experimental Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico San Raffaele, Milano, Italy;

6. Princess Alexandra Hospital, Brisbane, Australia;

7. University of Queensland, Brisbane, Australia;

8. Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany; and

9. Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany

Abstract

Key Points Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL. Updated results on safety and efficacy of the CLL8 trial.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/2/208/1351639/208.pdf

Reference32 articles.

1. Allotransplantation for chronic lymphocytic leukemia.;Dreger;Hematology Am Soc Hematol Educ Program,2009

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.;Hallek;Lancet,2010

3. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.;Fischer;J Clin Oncol,2012

4. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.;Goede;N Engl J Med,2014

5. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.;Foon;J Clin Oncol,2009

Cited by 586 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

2. Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia;Clinical and Translational Science;2024-08

3. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs;Cancers;2024-07-31

4. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies;Blood;2024-06-20

5. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10